JPMorgan Chase & Co. Increases Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM

JPMorgan Chase & Co. boosted its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 51.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,188,069 shares of the company’s stock after buying an additional 404,510 shares during the period. JPMorgan Chase & Co. owned approximately 1.78% of Rhythm Pharmaceuticals worth $119,983,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in RYTM. Adage Capital Partners GP L.L.C. bought a new position in shares of Rhythm Pharmaceuticals in the second quarter worth $21,548,000. Westfield Capital Management Co. LP lifted its holdings in Rhythm Pharmaceuticals by 21.5% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,629,468 shares of the company’s stock worth $102,966,000 after purchasing an additional 288,376 shares in the last quarter. Franklin Resources Inc. boosted its stake in Rhythm Pharmaceuticals by 66.7% in the 2nd quarter. Franklin Resources Inc. now owns 543,802 shares of the company’s stock worth $34,363,000 after purchasing an additional 217,642 shares during the period. Norges Bank purchased a new position in Rhythm Pharmaceuticals during the 2nd quarter valued at about $13,105,000. Finally, Alkeon Capital Management LLC increased its position in shares of Rhythm Pharmaceuticals by 24.5% during the second quarter. Alkeon Capital Management LLC now owns 1,017,700 shares of the company’s stock valued at $64,308,000 after buying an additional 200,000 shares during the period.

Wall Street Analysts Forecast Growth

RYTM has been the subject of a number of analyst reports. TD Cowen restated a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. Oppenheimer cut shares of Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 5th. The Goldman Sachs Group raised their price target on shares of Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the company a “buy” rating in a report on Friday, December 12th. Zacks Research raised shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. Finally, Wells Fargo & Company lifted their price objective on Rhythm Pharmaceuticals from $129.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $131.50.

Key Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: RBC/ Royal Bank initiated coverage and/or upgraded RYTM with an outperform/moderate-buy stance, bringing renewed institutional attention and a formal buy-style endorsement that can support near-term demand. RBC initiates coverage
• Positive Sentiment: Several sell-side firms have raised price targets and reiterated buy/overweight ratings (Wells Fargo, Morgan Stanley, Citizens/JMP, UBS, TD Cowen), reinforcing a bullish consensus and higher upside expectations. MarketBeat analyst roundup
• Positive Sentiment: Operational narrative improving: a Yahoo Finance piece highlights Imcivree revenue ramp and updated management targets — if execution continues, this supports medium-term revenue growth that underpins analyst optimism. Imcivree revenue and targets
• Neutral Sentiment: Zacks moved coverage from “strong sell” to “hold” and flagged RYTM as positioned to potentially beat upcoming earnings — these are watchpoints that reduce perceived downside but are not immediate catalysts without reported results. Zacks coverage and earnings outlook
• Negative Sentiment: Insider selling by CFO Hunter C. Smith: filings show sales of several thousand shares (transactions reported for Feb. 17 and Feb. 19 at ~ $101 per share). While the amounts are a small percentage of his total holding, such sales can trigger near-term selling pressure or investor concern about insider conviction. CFO sale disclosure

Insider Transactions at Rhythm Pharmaceuticals

In related news, insider Pamela J. Cramer sold 3,350 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $111.00, for a total transaction of $371,850.00. Following the transaction, the insider directly owned 20,814 shares of the company’s stock, valued at approximately $2,310,354. This trade represents a 13.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Hunter C. Smith sold 4,385 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the sale, the chief financial officer owned 110,512 shares of the company’s stock, valued at $11,190,445.12. The trade was a 3.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 25,003 shares of company stock worth $2,589,015 in the last 90 days. Company insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals Stock Performance

Rhythm Pharmaceuticals stock opened at $99.78 on Monday. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $45.90 and a fifty-two week high of $122.20. The stock has a market cap of $6.66 billion, a P/E ratio of -32.19 and a beta of 2.00. The firm’s fifty day moving average price is $105.41 and its 200-day moving average price is $103.50.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.